Discovery and Development of Second-Generation Proteasome Inhibitors

Ciechanover, 2005, Proteolysis: from the lysosome to ubiquitin and the proteasome, Nat Rev Mol Cell Biol, 6, 79, 10.1038/nrm1552 Goldberg, 2007, Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy, Biochem Soc Trans, 35, 12, 10.1042/BST0350012 Orlowski, 2005, Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies, Blood, 105, 3058, 10.1182/blood-2004-07-2911 Richardson, 2003, A phase 2 study of bortezomib in relapsed, refractory myeloma, N Engl J Med, 348, 2609, 10.1056/NEJMoa030288 Orlowski, 2008, Proteasome inhibitors in cancer therapy: lessons from the first decade, Clin Cancer Res, 14, 1649, 10.1158/1078-0432.CCR-07-2218 Navon, 2009, The 26 S proteasome: from basic mechanisms to drug targeting, J Biol Chem, 284, 33713, 10.1074/jbc.R109.018481 Borissenko, 2007, 20S proteasome and its inhibitors: crystallographic knowledge for drug development, Chem Rev, 107, 687, 10.1021/cr0502504 Kloetzel, 2004, Proteasome and peptidase function in MHC-class-I-mediated antigen presentation, Curr Opin Immunol, 16, 76, 10.1016/j.coi.2003.11.004 Griffin, 1998, Immunoproteasome assembly: cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits, J Exp Med, 187, 97, 10.1084/jem.187.1.97 Kloetzel, 2001, Antigen processing by the proteasome, Nat Rev Mol Cell Biol, 2, 179, 10.1038/35056572 Dick, 2010, Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy, Drug Discov Today, 15, 243, 10.1016/j.drudis.2010.01.008 Kupperman, 2010, Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer, Cancer Res, 70, 1970, 10.1158/0008-5472.CAN-09-2766 Piva, 2008, CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib, Blood, 111, 2765, 10.1182/blood-2007-07-100651 Dorsey, 2008, Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer, J Med Chem, 51, 1068, 10.1021/jm7010589 Sanchez, 2010, The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan, Br J Haematol, 148, 569, 10.1111/j.1365-2141.2009.08008.x Chauhan, 2011, In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells, Clin Cancer Res, 17, 5311, 10.1158/1078-0432.CCR-11-0476 Bringhen, 2010, Efficacy and safety of once-weekly bortezomib in multiple myeloma patients, Blood, 116, 4745, 10.1182/blood-2010-07-294983 Richardson, 2011, Investigational agent MLN9708, an oral proteasome inhibitor, in patients (Pts) with relapsed and/or refractory multiple myeloma (MM): results from the expansion cohorts of a phase 1 dose-escalation study, ASH Annual Meeting Abstracts, 118, 301 Kumar, 2011, weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients with relapsed and/or refractory multiple myeloma: results from a phase 1 dose-escalation study, ASH Annual Meeting Abstracts, 118, 816 Orlowski, 2002, Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies, J Clin Oncol, 20, 4420, 10.1200/JCO.2002.01.133 Papandreou, 2004, Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer, J Clin Oncol, 22, 2108, 10.1200/JCO.2004.02.106 Demo, 2007, Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome, Cancer Res, 67, 6383, 10.1158/0008-5472.CAN-06-4086 Groll, 2003, Crystal structure of epoxomicin:20S proteasome reveals a molecular basis for selectivity of a' b' - epoxyketone proteasome inhibitors, J Am Chem Soc, 122, 1237, 10.1021/ja993588m Mirabella, 2011, Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib, Chem Biol, 18, 608, 10.1016/j.chembiol.2011.02.015 Kuhn, 2007, Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma, Blood, 110, 3281, 10.1182/blood-2007-01-065888 Dasmahapatra, 2010, The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo, Blood, 115, 4478, 10.1182/blood-2009-12-257261 Zhou, 2009, Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047), J Med Chem, 52, 3028, 10.1021/jm801329v Sacco, 2011, Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's macroglobulinemia, Clin Cancer Res, 17, 1753, 10.1158/1078-0432.CCR-10-2130 Chauhan, 2010, A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma, Blood, 116, 4906, 10.1182/blood-2010-04-276626 Roccaro, 2010, Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia, Blood, 115, 4051, 10.1182/blood-2009-09-243402 Muchamuel, 2009, A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis, Nat Med, 15, 781, 10.1038/nm.1978 Parlati, 2009, Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome, Blood, 114, 3439, 10.1182/blood-2009-05-223677 Singh, 2011, PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo, Br J Haematol, 152, 155, 10.1111/j.1365-2141.2010.08491.x O'Connor, 2009, A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies, Clin Cancer Res, 15, 7085, 10.1158/1078-0432.CCR-09-0822 Alsina, 2007, Phase 1 single agent antitumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malignancies, ASH Annual Meeting Abstracts, 110, 411 Siegel, 2010, Results of PX-171-003-A1, an open-label, single-arm, phase 2 (Ph 2) study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM), ASH Annual Meeting Abstracts, 116, 985 Vij, 2011, Final results from the bortezomib-naive group of PX-171-004, a phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory MM, ASH Annual Meeting Abstracts, 118, 813 Papadopoulos, 2011, A phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors, ASCO Meeting Abstracts, 29, 3075 Groll, 2006, Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding, J Am Chem Soc, 128, 5136, 10.1021/ja058320b Chauhan, 2005, A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib, Cancer Cell, 8, 407, 10.1016/j.ccr.2005.10.013 Chauhan, 2010, Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma, Blood, 115, 834, 10.1182/blood-2009-03-213009 Cusack, 2006, NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model, Clin Cancer Res, 12, 6758, 10.1158/1078-0432.CCR-06-1151 Miller, 2009, Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells, Blood, 113, 4289, 10.1182/blood-2008-08-174797 Hofmeister, 2009, Clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory multiple myeloma (r/r MM), ASCO Meeting Abstracts, 27, 8505 Richardson, 2011, Phase 1 clinical evaluation of twice-weekly marizomib (NPI-0052), a novel proteasome inhibitor, in patients with relapsed/refractory multiple myeloma (MM), ASH Annual Meeting Abstracts, 118, 302 Millward, 2011, Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination, Invest New Drugs, 10.1007/s10637-011-9766-6 Britton, 2009, Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like situes, Chem Biol, 16, 1278, 10.1016/j.chembiol.2009.11.015 Mirabella, 2011, Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib, Chem Biol, 18, 608, 10.1016/j.chembiol.2011.02.015 Arastu-Kapur, 2011, Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events, Clin Cancer Res, 17, 2734, 10.1158/1078-0432.CCR-10-1950 Papadopoulos, 2010, Phase 1b evaluation of the safety and efficacy of a 30-minute IV infusion of carfilzomib in patients with relapsed and/or refractory multiple myeloma, ASH Annual Meeting Abstracts, 116, 3024 Miller, 2011, Specific and prolonged proteasome inhibition dictates apoptosis induction by marizomib and its analogs, Chem Biol Interact, 194, 58, 10.1016/j.cbi.2011.08.005 Bross, 2004, Approval summary for bortezomib for injection in the treatment of multiple myeloma, Clin Cancer Res, 10, 3954, 10.1158/1078-0432.CCR-03-0781 Lonial, 2005, Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma, Blood, 106, 3777, 10.1182/blood-2005-03-1173 Kirk, 2008, The selective proteasome inhibitor carfilzomib is well tolerated in experimental animals with dose intensive administration, ASH Annual Meeting Abstracts, 112, 2765 Cavaletti, 2010, Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies, Leuk Lymphoma, 51, 1178, 10.3109/10428194.2010.483303 Corso, 2010, Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients, Leuk Res, 34, 471, 10.1016/j.leukres.2009.07.022 Richardson, 2006, Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib, J Clin Oncol, 24, 3113, 10.1200/JCO.2005.04.7779 Cavaletti, 2007, Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat, Exp Neurol, 204, 317, 10.1016/j.expneurol.2006.11.010 Chao, 2008, Hax1-mediated processing of HtrA2 by Parl allows survival of lymphocytes and neurons, Nature, 452, 98, 10.1038/nature06604 Martins, 2004, Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice, Mol Cell Biol, 24, 9848, 10.1128/MCB.24.22.9848-9862.2004 Singhal, 2011, Integrated safety from phase 2 studies of monotherapy carfilzomib in patients with relapsed and refractory multiple myeloma (MM): an updated analysis, ASH Annual Meeting Abstracts, 118, 1876 Adams, 2004, The proteasome: a suitable antineoplastic target, Nat Rev Cancer, 4, 349, 10.1038/nrc1361 Hideshima, 2009, Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells, Blood, 114, 1046, 10.1182/blood-2009-01-199604 Walter, 2011, The unfolded protein response: from stress pathway to homeostatic regulation, Science, 334, 1081, 10.1126/science.1209038 Chapman, 2011, Initial genome sequencing and analysis of multiple myeloma, Nature, 471, 467, 10.1038/nature09837 Fernandez, 2005, Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications, Cancer Res, 65, 6294, 10.1158/0008-5472.CAN-05-0686 Qin, 2005, Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells, Cancer Res, 65, 6282, 10.1158/0008-5472.CAN-05-0676 Dasmahapatra, 2011, Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo, Mol Cancer Ther, 10, 1686, 10.1158/1535-7163.MCT-10-1108 Garrett, 2003, Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro, J Clin Invest, 111, 1771, 10.1172/JCI16198 Zangari, 2005, Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma, Br J Haematol, 131, 71, 10.1111/j.1365-2141.2005.05733.x Zangari, 2011, Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients, Eur J Haematol, 86, 484, 10.1111/j.1600-0609.2011.01602.x Groettrup, 2010, Proteasomes in immune cells: more than peptide producers?, Nat Rev Immunol, 10, 73, 10.1038/nri2687